Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

@article{Sports2008AdministrationOR,
  title={Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets},
  author={Claude Sport{\'e}s and Frances T Hakim and Sarfraz Memon and Hua Zhang and Kevin S. Chua and Margaret R. Brown and Thomas A. Fleisher and Michael C. Krumlauf and Rebecca R. Babb and Catherine K. Chow and Terry J Fry and Julie Engels and Renaud Buffet and Michel Morre and Robert J. Amato and David J Venzon and Robert Korngold and Andrew Pecora and Ronald E Gress and Crystal L Mackall},
  journal={The Journal of Experimental Medicine},
  year={2008},
  volume={205},
  pages={1701 - 1714}
}
Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts marked stimulating effects on T cell immune reconstitution in mice and primates. First-in-human clinical studies of recombinant human IL-7 (rhIL-7) provided the opportunity to investigate the effects of IL-7 therapy on lymphocytes in vivo. rhIL-7 induced in vivo T cell cycling, bcl-2 up-regulation, and a sustained… CONTINUE READING